Skip to main content
Top
Published in: Clinical Rheumatology 5/2018

01-05-2018 | Original Article

Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value

Authors: Serena Vettori, Salvatore Tolone, Domenico Capocotta, Rossella Chieffo, Veronica Giacco, Gabriele Valentini, Ludovico Docimo

Published in: Clinical Rheumatology | Issue 5/2018

Login to get access

Abstract

This study aims to investigate pre-clinical esophageal involvement in systemic sclerosis (SSc) by high-resolution impedance manometry (HRiM), its associations with disease features including lung involvement, and its predictivity of esophageal symptoms overtime. Charts of 45 asymptomatic (no heartburn/regurgitation/dysphagia) SSc patients (96% females; mean age 46 years) with at least one follow-up (FU) visit and complete clinical, serological, functional, and radiological assessment, including high-resolution computed tomography (HRCT) of the chest and lung function tests, that had undergone esophageal HRiM were retrospectively evaluated. Esophagogastric junction-contractile integral (EGJ-CI) and esophageal body motility, as evaluated by mean distal contractile integral (DCI), were assessed. SSc patients had a normal esophageal motility in 7/45 cases, a defective EGJ-CI in 28, an ineffective esophageal motility (IEM) in 17, and aperistalsis in 12. Defective EGJ-CI was associated with IEM/aperistalsis in 20 cases, while 9 patients had isolated IEM. Defective EGJ-CI and/or IEM/aperistalsis were associated with a diffusing lung capacity for CO < 80% of predicted value (all p < 0.05), while defective EGJ-CI was also associated with interstitial lung disease on HRCT (p = 0.03). Prevalence of any HRiM abnormality was higher in anti-centromere antibody negative patients (all p < 0.05). IEM/aperistalsis independently increased the risk of esophageal symptoms by 2.3-fold (95% CI 1.1–5.7) and was associated with their higher cumulative incidence with respect to patients with other HRiM patterns at FU (χ2 = 4.63; p = 0.03). SSc patients asymptomatic for esophageal involvement can have HRiM abnormalities in up to 84% of cases. A baseline-impaired motility is a risk factor for symptomatic esophageal disease.
Appendix
Available only for authorised users
Literature
2.
go back to reference Trojanowska M (2010) Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 6:453–460CrossRefPubMed Trojanowska M (2010) Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 6:453–460CrossRefPubMed
4.
go back to reference Forbes A, Marie I (2009) Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) 48(S3):iii36–iii39 Forbes A, Marie I (2009) Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) 48(S3):iii36–iii39
5.
go back to reference Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O, Riemekasten G, Valentini G, Müller-Ladner U, Co-authors EUSTAR (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355–1360CrossRefPubMed Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O, Riemekasten G, Valentini G, Müller-Ladner U, Co-authors EUSTAR (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355–1360CrossRefPubMed
6.
go back to reference Ebert EC (2008) Esophageal disease in progressive systemic sclerosis. Curr Treat Options Gastroenterol 11:64–69CrossRefPubMed Ebert EC (2008) Esophageal disease in progressive systemic sclerosis. Curr Treat Options Gastroenterol 11:64–69CrossRefPubMed
7.
go back to reference Sjogren RW (1994) Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 37:1265–1282CrossRefPubMed Sjogren RW (1994) Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 37:1265–1282CrossRefPubMed
8.
go back to reference Sallam H, McNearney TA, Chen JD (2006) Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 23:691–712CrossRefPubMed Sallam H, McNearney TA, Chen JD (2006) Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 23:691–712CrossRefPubMed
9.
go back to reference Pandolfino JE, Kahrilas PJ (2009) New technologies in the gastrointestinal clinic and research: impedance and high-resolution manometry. World J Gatroenterol 15:131–138CrossRef Pandolfino JE, Kahrilas PJ (2009) New technologies in the gastrointestinal clinic and research: impedance and high-resolution manometry. World J Gatroenterol 15:131–138CrossRef
10.
go back to reference Carlson DA, Hinchcliff M, Pandolfino JE (2015) Advances in the evaluation and management of esophageal disease of systemic sclerosis. Curr Rheumatol Rep 17:475–485CrossRefPubMedPubMedCentral Carlson DA, Hinchcliff M, Pandolfino JE (2015) Advances in the evaluation and management of esophageal disease of systemic sclerosis. Curr Rheumatol Rep 17:475–485CrossRefPubMedPubMedCentral
11.
go back to reference Raja J, Ng CT, Sujau I, Chin KF, Sockalingam S (2016) High-resolution oesophageal manometry and 24-hour impedance-pH study in systemic sclerosis patients: association with clinical features, symptoms and severity. Clin Exp Rheumatol 34(S100):115–121PubMed Raja J, Ng CT, Sujau I, Chin KF, Sockalingam S (2016) High-resolution oesophageal manometry and 24-hour impedance-pH study in systemic sclerosis patients: association with clinical features, symptoms and severity. Clin Exp Rheumatol 34(S100):115–121PubMed
12.
go back to reference Kimmel JN, Carlson DA, Hinchcliff M, Carns MA, Aren KA, Lee J, Pandolfino JE (2016) The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. Neurogastroenterol Motil 28:1157–1165CrossRefPubMedPubMedCentral Kimmel JN, Carlson DA, Hinchcliff M, Carns MA, Aren KA, Lee J, Pandolfino JE (2016) The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. Neurogastroenterol Motil 28:1157–1165CrossRefPubMedPubMedCentral
13.
go back to reference Carlson DA, Crowell MD, Kimmel JN, Patel A, Gyawali CP, Hinchcliff M, Griffing WL, Pandolfino JE, Vela MF (2016) Loss of peristaltic reserve, determined by multiple rapid swallows is the most frequent esophageal motility abnormality in patients with systemic sclerosis. Clin Gastroenterol Hepatol 14:1502–1506CrossRefPubMedPubMedCentral Carlson DA, Crowell MD, Kimmel JN, Patel A, Gyawali CP, Hinchcliff M, Griffing WL, Pandolfino JE, Vela MF (2016) Loss of peristaltic reserve, determined by multiple rapid swallows is the most frequent esophageal motility abnormality in patients with systemic sclerosis. Clin Gastroenterol Hepatol 14:1502–1506CrossRefPubMedPubMedCentral
14.
go back to reference Karamanolis GP, Panopoulos S, Karlaftis A, Denaxas K, Kamberoglou D, Sfikakis PP, Ladas SD (2015) Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: a pilot study. United European Gastroenterol J 3:266–271CrossRefPubMedPubMedCentral Karamanolis GP, Panopoulos S, Karlaftis A, Denaxas K, Kamberoglou D, Sfikakis PP, Ladas SD (2015) Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: a pilot study. United European Gastroenterol J 3:266–271CrossRefPubMedPubMedCentral
15.
go back to reference Karamanolis GP, Panopoulos S, Denaxas K, Karlaftis A, Zorbala A, Kamberoglou D, Ladas SD, Sfikakis PP (2016) The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Arthritis Res Ther 18:195CrossRefPubMedPubMedCentral Karamanolis GP, Panopoulos S, Denaxas K, Karlaftis A, Zorbala A, Kamberoglou D, Ladas SD, Sfikakis PP (2016) The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Arthritis Res Ther 18:195CrossRefPubMedPubMedCentral
16.
go back to reference Luciano L, Granel B, Bernit E, Harle JR, Baumstarck K, Grimaud JC, Bouvier M, Vitton V (2016) Esophageal and anorectal involvement in systemic sclerosis: a systematic assessment with highresolution manometry. Clin Exp Rheumatol 34 S(100):63–69 Luciano L, Granel B, Bernit E, Harle JR, Baumstarck K, Grimaud JC, Bouvier M, Vitton V (2016) Esophageal and anorectal involvement in systemic sclerosis: a systematic assessment with highresolution manometry. Clin Exp Rheumatol 34 S(100):63–69
17.
go back to reference Crowell MD, Umar SB, Griffing WL, DiBaise JK, Lacy BE, Vela MF (2017) Esophageal motor abnormalities in patients with scleroderma: heterogeneity, risk factors, and effects on quality of life. Clin Gastroenterol Hepatol 15:207–213CrossRefPubMed Crowell MD, Umar SB, Griffing WL, DiBaise JK, Lacy BE, Vela MF (2017) Esophageal motor abnormalities in patients with scleroderma: heterogeneity, risk factors, and effects on quality of life. Clin Gastroenterol Hepatol 15:207–213CrossRefPubMed
19.
go back to reference Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755CrossRefPubMed Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755CrossRefPubMed
20.
go back to reference Bogte A, Bredenoord AJ, Oors J, Siersema PD, Smout AJ (2013) Normal values for esophageal high-resolution manometry. Neurogastroenterol Motil 25:762–e579CrossRefPubMed Bogte A, Bredenoord AJ, Oors J, Siersema PD, Smout AJ (2013) Normal values for esophageal high-resolution manometry. Neurogastroenterol Motil 25:762–e579CrossRefPubMed
21.
go back to reference Weijenborg PW, Kessing BF, Smout AJ, Bredenoord AJ (2014) Normal values for solid-state esophageal high-resolution manometry in a European population; an overview of all current metrics. Neurogastroenterol Motil 26:654–659CrossRefPubMed Weijenborg PW, Kessing BF, Smout AJ, Bredenoord AJ (2014) Normal values for solid-state esophageal high-resolution manometry in a European population; an overview of all current metrics. Neurogastroenterol Motil 26:654–659CrossRefPubMed
22.
go back to reference Savarino E, de Bortoli N, Bellini M, Galeazzi F, Ribolsi M, Salvador R, Savarino V, Penagini R (2016) Practice guidelines on the use of esophageal manometry—a GISMAD-SIGE-AIGO medical position statement. Dig Liver Dis 48:1124–1135CrossRefPubMed Savarino E, de Bortoli N, Bellini M, Galeazzi F, Ribolsi M, Salvador R, Savarino V, Penagini R (2016) Practice guidelines on the use of esophageal manometry—a GISMAD-SIGE-AIGO medical position statement. Dig Liver Dis 48:1124–1135CrossRefPubMed
23.
go back to reference LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
24.
go back to reference Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A, Cozzolino D, del Genio G, Santoriello C (2011) Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 50:317–323CrossRef Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A, Cozzolino D, del Genio G, Santoriello C (2011) Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 50:317–323CrossRef
25.
go back to reference Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 66:754–763CrossRefPubMedPubMedCentral Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 66:754–763CrossRefPubMedPubMedCentral
26.
go back to reference Tolone S, de Cassan C, de Bortoli N, Roman S, Galeazzi F, Salvador R, Marabotto E, Furnari M, Zentilin P, Marchi S, Bardini R, Sturniolo GC, Savarino V, Savarino E (2015) Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD. Neurogastroenterol Motil 27:1175–1182CrossRefPubMed Tolone S, de Cassan C, de Bortoli N, Roman S, Galeazzi F, Salvador R, Marabotto E, Furnari M, Zentilin P, Marchi S, Bardini R, Sturniolo GC, Savarino V, Savarino E (2015) Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD. Neurogastroenterol Motil 27:1175–1182CrossRefPubMed
27.
go back to reference Do Carmo GC, Jafari J, Sifrim D, De Oliveira RB (2015) Normal esophageal pressure topography metrics for data derived from the Sandhill-Unisensor high-resolution manometry assembly in supine and sitting positions. Neurogastroenterol Motil 27:285–292CrossRefPubMed Do Carmo GC, Jafari J, Sifrim D, De Oliveira RB (2015) Normal esophageal pressure topography metrics for data derived from the Sandhill-Unisensor high-resolution manometry assembly in supine and sitting positions. Neurogastroenterol Motil 27:285–292CrossRefPubMed
28.
go back to reference Tolone S, de Bortoli N, Marabotto E, de Cassan C, Bodini G, Roman S, Furnari M, Savarino V, Docimo L, Savarino E (2015) Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? Neurogastroenterol Motil 27:1423–1431CrossRefPubMed Tolone S, de Bortoli N, Marabotto E, de Cassan C, Bodini G, Roman S, Furnari M, Savarino V, Docimo L, Savarino E (2015) Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? Neurogastroenterol Motil 27:1423–1431CrossRefPubMed
29.
go back to reference Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ et al (2015) The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 27:160–174CrossRefPubMed Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ et al (2015) The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 27:160–174CrossRefPubMed
30.
go back to reference Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, Valentini G (2015) Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. Semin Arthritis Rheum 44:437–444CrossRefPubMed Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, Valentini G (2015) Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. Semin Arthritis Rheum 44:437–444CrossRefPubMed
31.
go back to reference Valentini G, Marcoccia A, Cuomo G, Vettori S, Iudici M, Bondanini F, Santoriello C, Ciani A, Cozzolino D, de Matteis GM, Cappabianca S, Vitelli F, Spanò A (2014) Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity. Arthritis Care Res (Hoboken) 66:1520–1527CrossRef Valentini G, Marcoccia A, Cuomo G, Vettori S, Iudici M, Bondanini F, Santoriello C, Ciani A, Cozzolino D, de Matteis GM, Cappabianca S, Vitelli F, Spanò A (2014) Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity. Arthritis Care Res (Hoboken) 66:1520–1527CrossRef
32.
go back to reference Kinuja K, Nakajima K, Kinuja S et al (2001) Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nucl Med 15:97–101CrossRef Kinuja K, Nakajima K, Kinuja S et al (2001) Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nucl Med 15:97–101CrossRef
33.
go back to reference Airò P, Della Casa D, Danieli E, Missale G, Cattaneo R, Cestari R (2005) Oesophageal manometry in early and definite systemic sclerosis. Clin Rheumatol 24(4):370–376CrossRefPubMed Airò P, Della Casa D, Danieli E, Missale G, Cattaneo R, Cestari R (2005) Oesophageal manometry in early and definite systemic sclerosis. Clin Rheumatol 24(4):370–376CrossRefPubMed
34.
go back to reference Kaye SA, Siraj QH, Agnew J, Hilson A, Black CM (1996) Detection of early asymptomatic esophageal dysfunction in systemic sclerosis using a new scintigraphic grading method. J Rheumatol 23(2):297–301PubMed Kaye SA, Siraj QH, Agnew J, Hilson A, Black CM (1996) Detection of early asymptomatic esophageal dysfunction in systemic sclerosis using a new scintigraphic grading method. J Rheumatol 23(2):297–301PubMed
35.
go back to reference Lock G, Pfeifer M, Straub RH, Zeuner M, Lang B, Schölmerich J, Holstege A (1998) Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 93(3):341–345CrossRefPubMed Lock G, Pfeifer M, Straub RH, Zeuner M, Lang B, Schölmerich J, Holstege A (1998) Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 93(3):341–345CrossRefPubMed
36.
go back to reference Marie I, Dominique S, Levesque H, Ducrotté P, Denis P, Hellot MF, Courtois H (2001) Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 45(4):346–354CrossRefPubMed Marie I, Dominique S, Levesque H, Ducrotté P, Denis P, Hellot MF, Courtois H (2001) Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 45(4):346–354CrossRefPubMed
37.
go back to reference Zhang XJ, Bonner A, Hudson M, Canadian Scleroderma Research Group, Baron M, Pope J (2013) Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. J Rheumatol 40(6):850–858CrossRefPubMed Zhang XJ, Bonner A, Hudson M, Canadian Scleroderma Research Group, Baron M, Pope J (2013) Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. J Rheumatol 40(6):850–858CrossRefPubMed
38.
go back to reference Gilson M, Zerkak D, Wipff J, Dusser D, Dinh-Xuan AT, Abitbol V, Chaussade S, Legmann P, Kahan A, Allanore Y (2010 Jan) Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 35(1):112–117CrossRefPubMed Gilson M, Zerkak D, Wipff J, Dusser D, Dinh-Xuan AT, Abitbol V, Chaussade S, Legmann P, Kahan A, Allanore Y (2010 Jan) Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 35(1):112–117CrossRefPubMed
39.
go back to reference Hongo M, Traube M, McAllister RG Jr, McCallum RW (1984) Effects of nifedipine on esophageal motor function in humans: correlation with plasma nifedipine concentrations. Gastroentrology 86:8–12 Hongo M, Traube M, McAllister RG Jr, McCallum RW (1984) Effects of nifedipine on esophageal motor function in humans: correlation with plasma nifedipine concentrations. Gastroentrology 86:8–12
40.
go back to reference Ruigomez A, Rodriguez LAG, Wallander MA, Johansson S, Eklund S (2006) Esophageal stricture: incidence, treatment patterns, and recurrence rate. Am J Gastroenterol 101:2685–2692CrossRefPubMed Ruigomez A, Rodriguez LAG, Wallander MA, Johansson S, Eklund S (2006) Esophageal stricture: incidence, treatment patterns, and recurrence rate. Am J Gastroenterol 101:2685–2692CrossRefPubMed
41.
go back to reference Kessing BF, Smout AJPM, Bennink RJ, Kraaijpoel N, Oors JM, Bredenoord AJ (2014) Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neuorgastroenterol Motil 26:1079–1086CrossRef Kessing BF, Smout AJPM, Bennink RJ, Kraaijpoel N, Oors JM, Bredenoord AJ (2014) Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neuorgastroenterol Motil 26:1079–1086CrossRef
Metadata
Title
Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value
Authors
Serena Vettori
Salvatore Tolone
Domenico Capocotta
Rossella Chieffo
Veronica Giacco
Gabriele Valentini
Ludovico Docimo
Publication date
01-05-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 5/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4026-1

Other articles of this Issue 5/2018

Clinical Rheumatology 5/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.